Treatment of Coronavirus Disease 2019—Evidence-based or Personalized Medicine?
Authors:
Open Access
- 15 July 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, ChinaJAMA Cardiology, 2020
- D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19Journal of Thrombosis and Haemostasis, 2020
- Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesThe Lancet Infectious Diseases, 2020
- Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, FranceTravel Medicine and Infectious Disease, 2020
- Against pandemic research exceptionalismScience, 2020
- Cytokine release syndrome in severe COVID-19Science, 2020
- Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysisClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Evidence-Based Medicine Versus Personalized MedicineJournal of Clinical Psychopharmacology, 2012
- Evidence-Based MedicineJAMA, 1992